EGLN1 and anemia (phenotype): The modulation of the activity of these enzymes could be beneficial for the treatment of a variety of diseases, therefore, a large number of PHD2 inhibitors have been developed and are now in late stage clinical trials for the treatment of anemia and chronic kidney diseases [8–13].